The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response

被引:5
|
作者
Mandish, Steven F. [1 ]
Gaskins, Jeremy T. [2 ]
Yusuf, Mehran B. [1 ]
Amer, Yomna M. [3 ]
Eldredge-Hindy, Harriet [1 ]
机构
[1] Univ Louisville Hosp, Dept Radiat Oncol, Louisville, KY USA
[2] Univ Louisville, Dept Bioinformat & Biostat, Louisville, KY 40202 USA
[3] Univ Louisville, Sch Med, Louisville, KY 40202 USA
关键词
RADIATION-THERAPY; CANCER; STAGE; IRRADIATION; DISTANCE; OUTCOMES; IMPACT; TRASTUZUMAB; POPULATION; CARCINOMA;
D O I
10.1080/0284186X.2020.1797161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective(s) Neoadjuvant chemotherapy (NAC) is a standard of care for locally advanced breast cancers. Adjuvant radiotherapy (RT) after NAC is an area of active research. We hypothesize overall survival (OS) is not altered by omitting RT in women with a pathologic complete response (pCR) to NAC after breast conserving survery (BCS). Methods Patients from the National Cancer Database who underwent NAC, BCS, and had a pCR were included. Inflammatory disease, <6 months follow up, and unknown variables were excluded. Descriptive statistics characterized the retained cohort. Logistic regression analyzed the influence of variables on the rate of RT omission. Cox proportional hazard modeling analyzed the influence of prognostic variables on OS. Results Of 5383 women included, 364 (7%) omitted RT. 5-year OS was 94.1% with RT, 93% without. RT omission was most likely in women >70yo (adjusted OR2.4, 95%CI 1.58-3.65,p < .0001;reference 40-49 yo), Hispanic (AOR 1.73, 95%CI 1.19-2.52,p = .0044; reference non-Hispanic), >= 20 miles from treatment facility (20-49 miles; AOR 1.45, 95%CI 1.09-1.93,p = .0109: >50 miles; AOR 2.02, 95%CI 1.42-2.87,p < .0001;reference 0-19 miles), grade 1 (AOR 4.29, 95%CI 2.16-8.51,p < .0001; reference grade 3), and clinical T4 disease (AOR 3.17, 95%CI 1.74-5.79,p = .0002; reference T0/1). Women >= 60yo (60-69: AHR 2.33, 95%CI 1.41-3.83,p = .0009:70+:AHR 2.4, 95%CI 1.24-4.62,p = .0092; reference 40-49) and with N1 and N3 disease (N1: AHR 1.67, 95% CI 2.28-3.24,p = .0034; N3: AHR3.37,95%CI2.01-5.65,p < .0001) showed increased death. Triple-positive (AHR 0.18, 95%CI 0.07-0.43,p = .0002) and HER2+ patients (AHR 0.44, 95%CI 0.30-0.64,p < .0001) had improved OS compared to triple-negative disease. No survival difference was seen with omission of RT (log-rank test:p = .1783; Cox model AHR 1.33, 95%CI 0.76-2.31,p = .3181). Conclusion Women >= 70, of Hispanic origin, living >= 20 miles from treatment facility, and grade 1 disease were more likely to omit RT. HER2+ patients had favorable OS, while older age and N3 disease were negative prognostic factors. Omitting RT after a pCR to NAC and BCS was not found to affect OS.
引用
收藏
页码:1210 / 1217
页数:8
相关论文
共 50 条
  • [41] Bisphosphonates and Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
    Gregor, M. Chavez-Mac
    Brown, E. N.
    Lei, X.
    Hsu, L.
    Meric-Bernstam, F.
    Litton, J.
    Mittendorf, E. A.
    Valero, V.
    Hortobagyi, G. N.
    Gonzalez-Angulo, A. M.
    CANCER RESEARCH, 2010, 70
  • [42] Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Li, Xiaoxian Bill
    Krishnamurti, Uma
    Bhattarai, Shristi
    Ktimov, Sergey
    Reid, Michelle D.
    O'Regan, Ruth
    Aneja, Ritu
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 145 (06) : 871 - 878
  • [43] IS RADIOTHERAPY AN OPTION FOR EARLY BREAST CANCERS WITH COMPLETE CLINICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY?
    Daveau, Caroline
    Savignoni, Alexia
    Abrous-Anane, Soumya
    Pierga, Jean-Yves
    Reyal, Fabien
    Gautier, Chantal
    Kirova, Youlia M.
    Dendale, Remi
    Campana, Francois
    Fourquet, Alain
    Bollet, Marc A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (05): : 1452 - 1459
  • [44] Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
    Schaefgen, B.
    Mati, M.
    Sinn, H. P.
    Golatta, M.
    Stieber, A.
    Rauch, G.
    Hennigs, A.
    Richter, H.
    Domschke, C.
    Schuetz, F.
    Sohn, C.
    Schneeweiss, A.
    Heil, Joerg
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (03) : 789 - 795
  • [45] Pathologic Complete Response Rate and Clinical Outcome of Metaplastic Breast Carcinoma After Neoadjuvant Chemotherapy
    Han, Min
    Zhang, Huina
    Clark, Beth
    Dabbs, David
    Bhargava, Rohit
    MODERN PATHOLOGY, 2018, 31 : 67 - 68
  • [46] Pathologic Complete Response Rate and Clinical Outcome of Metaplastic Breast Carcinoma After Neoadjuvant Chemotherapy
    Han, Min
    Zhang, Huina
    Clark, Beth
    Dabbs, David
    Bhargava, Rohit
    LABORATORY INVESTIGATION, 2018, 98 : 67 - 68
  • [47] A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy
    Alan, Ozkan
    Telli, Tugba Akin
    Ercelep, Ozlem
    Hasanov, Rahib
    Simsek, Eda Tanrikulu
    Mutis, Aydan
    Ones, Tunc
    Kaya, Handan
    Yumuk, Perran Fulden
    CURRENT PROBLEMS IN CANCER, 2019, 43 (04) : 308 - 311
  • [48] Survival and recurrence of breast cancer patients with pathologic complete response after neoadjuvant chemotherapy.
    Lee, Young Joo
    Ahn, Sei-Hyun
    Sohn, Byung Ho
    Lee, Jong Won
    Chung, Il Yong
    Ko, Beom Seok
    Kim, Hee Jeong
    Kim, Jisun
    Lee, Sae Byul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Correlation of pathologic and radiologic complete response in the axilla after neoadjuvant chemotherapy for breast cancer.
    Gooch, Jessica Charlotte
    Borjas, Timothy
    Kim, Jennifer Chun
    Yakes, Alexis
    Jubas, Talia
    Axelrod, Deborah M.
    Guth, Amber
    Hiotis, Karen
    Shapiro, Richard L.
    Moy, Linda
    Schnabel, Freya Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] The impact of tumor microenviroment on pathologic complete response after neoadjuvant chemotherapy of early breast cancer
    Kuhar, C. Grasic
    Gazic, B.
    Ivancic, A. Klevisar
    Drev, P.
    Vetter, M. H. F.
    Kurzeder, C.
    Gersak, K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S611 - S611